June 25 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS PROVIDES REGULATORY UPDATE ON ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE AND DEMENTIA WITH LEWY BODIES $(DLB)$
COGNITION THERAPEUTICS INC - TO CONDUCT END-OF-PHASE 2 MEETING WITH FDA ON JULY 9, 2025
Source text: ID:nGNX2qzmb3
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.